<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176991</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-1601-101</org_study_id>
    <nct_id>NCT04176991</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia</brief_title>
  <official_title>A Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Larimar Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veristat, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Metrum Research Group, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Larimar Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of single ascending doses of CTI-1601 in participants&#xD;
      with Friedreich's ataxia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single Ascending Dose (SAD), Double-Blind, Placebo Controlled Study.&#xD;
&#xD;
      To evaluate the safety and tolerability of single ascending doses of CTI-1601 in subjects&#xD;
      with Friedreich's ataxia.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To evaluate the pharmacokinetics (PK) of CTI-1601 following increasing single doses of&#xD;
           subcutaneously (SC) administered CTI-1601.&#xD;
&#xD;
        2. To evaluate the pharmacodynamics (PD) of CTI-1601 following increasing single doses of&#xD;
           SC administered CTI-1601.&#xD;
&#xD;
      CTI-1601 or Placebo - Dose/Mode of Administration: Single Dose/Subcutaneous&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 11, 2019</start_date>
  <completion_date type="Actual">October 31, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment-Emergent Adverse Events</measure>
    <time_frame>Through study completion, an average of 70 days</time_frame>
    <description>Overall summary of the Participants with Treatment Emergent Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment Emergent Adverse Events by System Organ Classification and Preferred Term</measure>
    <time_frame>Through study completion, an average of 70 days</time_frame>
    <description>Overall summary of Participants with Treatment Emergent Adverse Events by System Organ Classification (MedDRA version 22.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area under the concentration-time curve after a single dose</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Summary assessment of changes in the area under the concentration-time curve after a single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Maximum observed plasma concentration after a single dose</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Summary assessment of changes in the maximum observed plasma concentration after a single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Time to reach maximum plasma concentration after a single dose</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Summary assessment of changes in time to reach maximum plasma concentration after a single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area under the concentration-time curve from time 0 to infinity</measure>
    <time_frame>48 hours</time_frame>
    <description>Summary assessment of changes in the area under the concentration-time curve from time 0 to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area under the concentration-time curve from time 0 to the last measurable time point</measure>
    <time_frame>48 hours</time_frame>
    <description>Summary assessment of changes in the Area under the concentration-time curve from time 0 to the last measurable time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Apparent total plasma clearance</measure>
    <time_frame>48 hours</time_frame>
    <description>Summary assessment of changes in the apparent total plasma clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Terminal half-life estimation</measure>
    <time_frame>48 hours</time_frame>
    <description>Summary assessment of changes in the terminal half-life estimation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Apparent volume of distribution</measure>
    <time_frame>48 hours</time_frame>
    <description>Summary assessment of changes in the apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Frataxin Levels in Buccal Cells</measure>
    <time_frame>At baseline and up to 10 days</time_frame>
    <description>Summary assessment of changes in frataxin levels in buccal cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Frataxin Levels in Whole Blood</measure>
    <time_frame>At baseline and up to 10 days</time_frame>
    <description>Summary assessment of changes in frataxin levels in whole blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Gene Expression Profiling</measure>
    <time_frame>At baseline and up to 10 days</time_frame>
    <description>Summary assessment of changes in gene expression levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Friedreich Ataxia</condition>
  <arm_group>
    <arm_group_label>CTI-1601</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTI-1601</intervention_name>
    <description>CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia</description>
    <arm_group_label>CTI-1601</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has genetically confirmed Friedreich's ataxia diagnosis, homozygous GAA repeat&#xD;
             expansions, with repeat sizing (if available) included on diagnostic report.&#xD;
&#xD;
          2. Subject is male or female, 18 years of age or older at screening.&#xD;
&#xD;
          3. Subject must have a mFARS_neuro score â‰¥ 20 and be able to traverse a distance of 25&#xD;
             feet with or without some assistive device (cane, walker, crutches, self-propelled&#xD;
             wheelchair) and (a) be able to sit upright with thighs together and arms crossed&#xD;
             without requiring support on more than two sides; (b) be able to transfer from bed to&#xD;
             chair independently or with minimal assistance if, in the opinion of the investigator,&#xD;
             the degree of physical disability does not result in undue risk to the subject while&#xD;
             participating in the study; and (c) perform basic daily care, such as feeding&#xD;
             themselves and personal hygiene, with minimal assistance.&#xD;
&#xD;
          4. Subjects must weigh &gt; 40 kilograms (kg).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who are confirmed as compound heterozygous (GAA repeat expansion on only one&#xD;
             allele) for Friedreich's ataxia.&#xD;
&#xD;
          2. Subject requires use of amiodarone.&#xD;
&#xD;
          3. Subject used erythropoietin, etravirine, or gamma interferon within 3 months prior to&#xD;
             screening.&#xD;
&#xD;
          4. Subject use of investigational drug (other than CTI-1601) or device within 90 days&#xD;
             prior to screening.&#xD;
&#xD;
          5. Subject use of daily biotin supplementation that exceeds 30 mcg/day, either as part of&#xD;
             a multivitamin or as a standalone supplement, within 7 days prior to study drug&#xD;
             administration and/or throughout the entire study.&#xD;
&#xD;
          6. Subject has clinically significant arrhythmia on electrocardiogram (ECG), or evidence&#xD;
             of predisposition to significant ventricular arrhythmia on ECG, or evidence of active&#xD;
             and unstable coronary artery disease.&#xD;
&#xD;
          7. Male subject who has an ECG QTcF &gt; 450 milliseconds or female subject who has an ECG&#xD;
             QTcF &gt; 470 milliseconds.&#xD;
&#xD;
          8. Subject has a screening echocardiogram ejection fraction &lt;45 percent.&#xD;
&#xD;
          9. Subject has a history of aspiration, aspiration pneumonia, or recurrent episodes of&#xD;
             pneumonia (greater than or equal to 2 episodes of pneumonia) within the last 12&#xD;
             months.&#xD;
&#xD;
         10. Subjects with known or suspected chronic use of cannabinoid products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinilabs Drug Development Corporation</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.curefa.org/</url>
    <description>Friedreich's Ataxia Research Alliance</description>
  </link>
  <reference>
    <citation>Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci. 2011 Apr 15;303(1-2):1-12. doi: 10.1016/j.jns.2011.01.010. Review.</citation>
    <PMID>21315377</PMID>
  </reference>
  <reference>
    <citation>Delatycki MB, Corben LA. Clinical features of Friedreich ataxia. J Child Neurol. 2012 Sep;27(9):1133-7. doi: 10.1177/0883073812448230. Epub 2012 Jun 29. Review.</citation>
    <PMID>22752493</PMID>
  </reference>
  <reference>
    <citation>Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil. 1988 Oct;69(10):850-4.</citation>
    <PMID>3178453</PMID>
  </reference>
  <reference>
    <citation>Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Clinical outcomes assessment in multiple sclerosis. Ann Neurol. 1996 Sep;40(3):469-79. Review.</citation>
    <PMID>8797541</PMID>
  </reference>
  <reference>
    <citation>Plasterer HL, Deutsch EC, Belmonte M, Egan E, Lynch DR, Rusche JR. Development of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich's ataxia. PLoS One. 2013 May 17;8(5):e63958. doi: 10.1371/journal.pone.0063958. Print 2013.</citation>
    <PMID>23691127</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

